[{"orgOrder":0,"company":"Medigene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Rhudex","moa":"Activation B7-1 antigen (CD80)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Medigene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Medigene \/ Undisclosed"},{"orgOrder":0,"company":"Medigene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"MDG1021","moa":"Antigen HA-1","graph1":"Oncology","graph2":"Phase I","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medigene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Medigene \/ Undisclosed"},{"orgOrder":0,"company":"Medigene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"MDG1021","moa":"Antigen HA-1","graph1":"Oncology","graph2":"Phase I","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medigene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Medigene \/ Undisclosed"},{"orgOrder":0,"company":"Medigene","sponsor":"Charit\u00e9 Research Organisation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Polyphenon E","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Medigene \/ Charit\u00e9 Research Organisation","highestDevelopmentStatusID":"11","companyTruncated":"Medigene \/ Charit\u00e9 Research Organisation"},{"orgOrder":0,"company":"Medigene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"MDG2011","moa":"KRAS G12V","graph1":"Oncology","graph2":"Discovery","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medigene \/ Undisclosed","highestDevelopmentStatusID":"2","companyTruncated":"Medigene \/ Undisclosed"},{"orgOrder":0,"company":"Medigene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"MDG1015","moa":"NY-ESO-1\/LAGE-1a","graph1":"Oncology","graph2":"Phase I","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medigene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Medigene \/ Undisclosed"},{"orgOrder":0,"company":"Medigene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"MDG1015","moa":"NY-ESO-1\/LAGE-1a","graph1":"Oncology","graph2":"IND Enabling","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medigene \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Medigene \/ Undisclosed"},{"orgOrder":0,"company":"Medigene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"MDG1015","moa":"NY-ESO-1\/LAGE-1a","graph1":"Oncology","graph2":"IND Enabling","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medigene \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Medigene \/ Undisclosed"},{"orgOrder":0,"company":"Medigene","sponsor":"AGC Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Agreement","leadProduct":"MDG1015","moa":"||NY-ESO-1\/LAGE-1a","graph1":"Oncology","graph2":"IND Enabling","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medigene \/ Medigene","highestDevelopmentStatusID":"5","companyTruncated":"Medigene \/ Medigene"},{"orgOrder":0,"company":"Medigene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Autologous Dendritic Cell Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medigene \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medigene \/ Undisclosed"},{"orgOrder":0,"company":"Medigene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"MDG1011","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medigene \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medigene \/ Undisclosed"},{"orgOrder":0,"company":"Medigene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"MDG1011","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medigene \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medigene \/ Undisclosed"},{"orgOrder":0,"company":"Medigene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"MDG2021","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medigene \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Medigene \/ Undisclosed"},{"orgOrder":0,"company":"Medigene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Plant Extract\/Herbal","year":"2011","type":"Inapplicable","leadProduct":"Sinecatechin","moa":"Immune||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Medigene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Medigene \/ Undisclosed"},{"orgOrder":0,"company":"Medigene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"WT1\/PRAME","moa":"WT1\/PRAME","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medigene \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medigene \/ Undisclosed"},{"orgOrder":0,"company":"Medigene","sponsor":"WuXi Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medigene \/ Medigene","highestDevelopmentStatusID":"4","companyTruncated":"Medigene \/ Medigene"},{"orgOrder":0,"company":"Medigene","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Medigene","amount2":1.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.02,"dosageForm":"Undisclosed","sponsorNew":"Medigene \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Medigene \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Medigene","sponsor":"Helmholtz Zentrum M\u00fcnchen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medigene \/ Medigene","highestDevelopmentStatusID":"2","companyTruncated":"Medigene \/ Medigene"},{"orgOrder":0,"company":"Medigene","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medigene \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"6","companyTruncated":"Medigene \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Medigene","sponsor":"2Seventy Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medigene \/ 2Seventy Bio","highestDevelopmentStatusID":"6","companyTruncated":"Medigene \/ 2Seventy Bio"},{"orgOrder":0,"company":"Medigene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medigene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Medigene \/ Undisclosed"},{"orgOrder":0,"company":"Medigene","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medigene \/ BioNTech","highestDevelopmentStatusID":"6","companyTruncated":"Medigene \/ BioNTech"},{"orgOrder":0,"company":"Medigene","sponsor":"EpimAb Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2025","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medigene \/ EpimAb Biotherapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Medigene \/ EpimAb Biotherapeutics"},{"orgOrder":0,"company":"Medigene","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medigene \/ BioNTech","highestDevelopmentStatusID":"6","companyTruncated":"Medigene \/ BioNTech"},{"orgOrder":0,"company":"Medigene","sponsor":"Medigene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medigene \/ Medigene","highestDevelopmentStatusID":"1","companyTruncated":"Medigene \/ Medigene"}]
Find Clinical Drug Pipeline Developments & Deals by Medigene
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
